Pharmaceutical - Pharmaceutical, Rare diseases

Filter

Popular Filters

1 to 25 of 311 results

FDA backs added indication for GSK’s Promacta

FDA backs added indication for GSK’s Promacta

27-08-2014

The Food and Drug Administration has approved UK pharma giant GlaxoSmithKline’s supplemental New Drug…

GlaxoSmithKlineHematologyLigand PharmaceuticalsPharmaceuticalPromactaRare diseasesRegulationRevoladeUSA

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

IQWiG finds added benefit for Novartis’ Jakavi in myelofibrosis

20-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products,…

Federal Joint CommitteeGermanyJakaviMyelofibrosisNovartisOncologyPharmaceuticalPricingRare diseasesRegulation

Prosensa and CureDuchenne expand DMD collaboration with $7 million funding boost

Prosensa and CureDuchenne expand DMD collaboration with $7 million funding boost

12-08-2014

Dutch biotech company Prosensa will receive a 5 million euros ($7 million) funding boost from US non-profit…

Duchenne Muscular DystrophyFinancialNetherlandsPharmaceuticalProsensaRare diseasesResearchUSA

Patient involvement pilot for orphan drugs launches in Canada

Patient involvement pilot for orphan drugs launches in Canada

07-08-2014

Canada’s Minister of Health, Rona Ambrose, says that the government has launched a pilot project targeting…

CanadaHealth CanadaPharmaceuticalRare diseasesRegulationResearchRocheTreatment of chronic lymphocytic leukemia

THERAMetrics and Centurion Pharma collaboration in rare diseases area

THERAMetrics and Centurion Pharma collaboration in rare diseases area

05-08-2014

Switzerland’s THERAMetrics holding and Turkish drugmaker Centurion Pharma plan to cooperate in the…

aviptadilCenturion PharmaIdiopathic pulmonary fibrosisLicensingPharmaceuticalRaffaele PetroneRare diseasesSarcoidosisTHERAMetricsTurkey

US and European orphan status for AbbVie’s glioblastoma candidate

US and European orphan status for AbbVie’s glioblastoma candidate

04-08-2014

Both the European Medicines Agency and the US Food and Drug Administration have granted orphan drug designation…

AbbVieABT-414Brain tumorEuropeGlioblastoma multiformeMarkets & MarketingOncologyPharmaceuticalRare diseasesRegulationUS Food and Drug AdministrationUSA

Kyowa Hakko Kirin files for KW-3357 approval in Japan

Kyowa Hakko Kirin files for KW-3357 approval in Japan

01-08-2014

Japanese drugmaker Kyowa Hakko Kirin has filed an application for marketing approval with the Ministry…

HematologyJapanKW-3357Kyowa Hakko KirinPharmaceuticalRare diseasesRegulationThrombus

Sanofi and Regeneron purchase FDA priority voucher for alirocumab

Sanofi and Regeneron purchase FDA priority voucher for alirocumab

31-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals intend to use a US Food…

alirocumabBioMarin PharmaceuticalFranceMajorPharmaceuticalRare diseasesRare pediatric diseasesRegeneronRegeneron PharmaceuticalsRegulationSanofiUSA

Roche joins forces with AmorChem on Steinert’s disease research

Roche joins forces with AmorChem on Steinert’s disease research

29-07-2014

Swiss drug major Roche and AmorChem, a Canadian venture capital firm investing in life science projects,…

AmorChemCanadaEnabling technologyEuropean UnionLicensingMajorMuscular dystrophyMyotonic dystrophyPharmaceuticalRare diseasesResearchRocheSwitzerland

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28-07-2014

The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors…

AfamelanotideAustraliaClinuvel PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinScenesse

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Orphan drug approvals rise, but high costs pose challenges for patients

Orphan drug approvals rise, but high costs pose challenges for patients

10-07-2014

Although the pace of approvals for new orphan drugs - medicines that treat relatively rare conditions…

EuropePharmaceuticalPricingRare diseasesRegulationUSA

EU orphan designations for OPKO's clotting Factor VIIa-CTP

EU orphan designations for OPKO's clotting Factor VIIa-CTP

10-07-2014

The European Committee for Orphan Medicinal Products (COMP) gave a positive opinion recommending the…

EuropeFactor VIIa-CTPHematologyOPKO HealthPharmaceuticalRare diseasesRegulation

Novo Nordisk gains FDA backing for new NovoSeven RT indication

Novo Nordisk gains FDA backing for new NovoSeven RT indication

09-07-2014

Danish diabetes care giant Novo Nordisk’s hemophilia treatment NovoSeven RT (coagulation factor VIIa…

HematologyNovo NordiskNovoSevenNovoSeven RTPharmaceuticalRare diseasesRegulationUSA

New Zealand proposes contestable fund for medicines for rare disorders

New Zealand proposes contestable fund for medicines for rare disorders

09-07-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC will be running a commercial process to fund…

FinancialNew ZealandPharmaceuticalRare diseasesRegulation

FDA orphan status for Insys’ cannabidiol as treatment for Dravet syndrome

FDA orphan status for Insys’ cannabidiol as treatment for Dravet syndrome

03-07-2014

US specialty pharma firm Insys Therapeutics yesterday revealed that the US Food and Drug Administration…

cannabidiolInsys TherapeuticsNeurologicalPharmaceuticalRare diseasesRegulationUSA

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

US orphan status for Insys Therapeutics’ cannabidiol for rare form of epilepsy

US orphan status for Insys Therapeutics’ cannabidiol for rare form of epilepsy

25-06-2014

US specialty pharma firm Insys Therapeutics says that the US Food and Drug Administration has granted…

cannabidiolInsys TherapeuticsNeurologicalPharmaceuticalRare diseasesRegulationUSA

Another $1 million GSK milestone for Isis Pharma

Another $1 million GSK milestone for Isis Pharma

24-06-2014

USA-based Isis Pharmaceuticals said today that it has earned a $1 million milestone payment from GlaxoSmithKline…

FinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR RxPharmaceuticalRare diseasesResearch

UK’s Summit sets up operations in the USA

UK’s Summit sets up operations in the USA

17-06-2014

UK drug discovery firm Summit, which is focused on therapies for Duchenne muscular dystrophy and Clostridium…

Antibiotics and Infectious diseasesBoardroomManagementPharmaceuticalRare diseasesResearchSummit PharmaceuticalsUSA

US orphan status for EffRx’ EX404 for pediatric polycystic ovary syndrome

US orphan status for EffRx’ EX404 for pediatric polycystic ovary syndrome

11-06-2014

Swiss drug delivery specialist EffRx Pharmaceuticals says the US Food and Drug Administration has granted…

EffRx PharmaceuticalsEX404metforminPharmaceuticalRare diseasesRegulationUSAWomen's Health

1 to 25 of 311 results

Back to top